Main Cell Secondary Cell Secondary Cell Secondary Cell Blur Cell Blur Cell Blur Cell Blur Cell Blur Cell

Our Science

We are led by experienced biopharma executives with exceptional track records of building strong companies, delivering innovative treatments and growing diverse teams.

Leaders in Immunology
Our Philosophy

Leaders in Immunology

We are building a portfolio of pre-clinical to late-stage assets with the potential to become the next great innovation in immunology, providing clinically meaningful treatments to patients.

We are guided by our values of courage, compassion, collaboration, innovation and a sense of urgency. We care as people, and we care as scientists.

The Right Blend
The Right Blend

We have the right blend of experience, along with a broad network of contacts, needed to advance programs that can dramatically transform patients’ lives.

Why ACELYRIN
Why ACELYRIN

We are building a different kind of biopharma company focused on developing and delivering therapeutics through efficient and ongoing collaboration.

Our Network
Our Network

ACELYRIN can access promising therapeutic programs through our global network of relationships across pharma and biotech, finance and academia.

Our Focus
Our Focus

We conduct a licensing and acquisition search process that is both directed and opportunistically focused on platforms, programs and products when compelling science or data exist.

Our Work

Accelerating Transformative Therapies

We are actively investigating the potential of izokibep and other programs in diseases where differentiated therapeutic approaches are required to address unmet patient needs.

Partnering with ACELYRIN
Partnering with ACELYRIN
Partnering with ACELYRIN

Partnering with ACELYRIN

Partnering with ACELYRIN Arrow white
For Investors
For Investors
For Investors

Maximizing Shareholder Value

For Investors Arrow white
News Center

The Latest Company
Announcements and Resources